Related Experiment Video
Updated: Jan 14, 2026

An Innovative 3D-Printed Insert Designed to Enable Straightforward 2D and 3D Cell Cultures
Published on: January 6, 2023
Effects of antiresorptives and Co-medications on 3D gingival cell Co-cultures
Heidi Maria Ekholm-Kerppola1, Eliisa Löyttyniemi2, Tero Soukka3
1Department of Oral Pathology and Oral Radiology, Institute of Dentistry, University of Turku, Turku, Finland.
Abstract:
IntroductionBisphosphonates and denosumab are the most common antiresorptive drugs (ARs). ARs may cause medication-related osteonecrosis of the jaw (MRONJ) as a side effect, characterized by osteonecrosis and ulceration of the oral mucosa. The pathophysiology of MRONJ remains partly unclear and there is currently no consensus on its multietiological background. Immunomodulatory medications such as corticosteroids and antiestrogens may affect MRONJ onset.MethodsAn in vitro 3D cell culture model of gingival, keratinocytes, and fibroblasts were used to elucidate the pathogenesis of MRONJ. Cell cultures were exposed to ARs, followed by exposures to corticosteroids or antiestrogens. Morphology and proliferation were evaluated.ResultsAmong the ARs, alendronate caused the most negative cellular changes, while zoledronate only had a few effects. Denosumab caused more morphological cell atypia and proliferation than other ARs. The combined exposures of individual ARs with corticosteroids had some additional negative effects on gingival cells, whereas ARs with antiestrogen had few effects. The results are partly inconsistent, indicating that 3D cell culture experiments may not be the most suitable method for studying the effects of ARs.ConclusionThis study suggests that alendronate and denosumab affect gingival cell growth in a 3D cell culture model. These effects are smaller than reported in previous monolayer studies.
More Related Videos
07:04Confocal Time Lapse Imaging as an Efficient Method for the Cytocompatibility Evaluation of Dental Composites
Published on: November 9, 2014
11:003D Flipwell Engineering for Developing Asynchronous Systems for Toxicologic and Immunomodulatory Therapies in Bacterial, Gut, and Immune Cells
Published on: October 17, 2025